Conference Day 2, May 23
9:00 am Check-In & Coffee
9:25 am Chair’s Opening Remarks
Evolution & Innovation: Navigating Recent Approvals, Charting Future Directions, & Brainstorming to Reduce Patient Burden
9:30 am Mapping the Past, Present, & Future of Cell Engager Therapies
Synopsis
- Revisit the recent development landscape of cell engagers within 7 recent approvals
- Understand which mechanisms, modalities, and formats are demonstrating promise towards developing the next approved cell engagers
- Reimagine future directions for cell engagers for both mono and combination therapies
10:00 am Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers
Synopsis
- Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies
- How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment?
- Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?
11:00 am Morning Refreshments & Networking
Pursuing the Next Generation of Cell Engagers to Create Robust Immune Responses
12:00 pm Developing a Highly Specific ImmTAC Against PIWIL1, a Promising Novel Colorectal Cancer Target
Synopsis
- Exploring a program case study accelerating towards clinic
- An overview of target selection processes and engineering to ensure specific and minimize off target activity
12:30 pm Accessing Intracellular Cancer Targets via Potent & Specific TCR Mimetic (TCRm)-Based T Cell Engagers
Synopsis
- Previously unreachable target classes amenable to TCRm-based T Cell engagers
- Differences and similarities between soluble TCR and TCRm-based T cell engager approaches
- Unique challenges and opportunities in developing TCRm-based T Cell Engagers
1:00 pm Lunch & Networking
Moving Beyond T-Cells & Unlocking More Immune Cells to Take Action & Drive Tumor Killing
2:00 pm Developing Ex Vivo Precision Gene Engineered B Cell Medicines to Create Sustainable Anti-Tumor Activity & Overcome Pharmacokinetic Shortcomings of BiTEs
Synopsis
- Exploring BiTE-expressing BECMs associated with reduced tumor burden in patientderived xenograft models
- Achieving clinically meaningful serum levels of BiTE
2:30 pm Exploiting Phagocytosis With Macrophage Engagers to Enhance Tumor Killing in Solid Tumors
Synopsis
- Advantage of inducing cancer death and clearance by implementing macrophage phagocytosis as compared to T cell engagers
- Explore the development challenges of macrophage engagers in comparison to alternate cell types
- Utilize innate immune cells for improved targeting of cancers in solid tumors
Exploring Co-Stimulation & Integrated Immune Signaling During Cell Engager Development to Induce Long-Lasting Immune Memory
3:00 pm Mastering Immune Potency Through Integration of Co-Stimulation for Improved Immune Cell Activity to Enhance Cytotoxicity
Synopsis
- Improving T cell activity beyond initial activation through integrating co-stimulation into biologics development for improved memory response and reduce risk of relapse or resistance
- Enhancing cytotoxicity and synergy with checkpoint inhibitors to sustain adaptability to cancer types
- What are the right co-stimulatory responses to activate solid tumor treatment?